Calliditas Therapeutics
As of the edition of 20 October 2026, Calliditas Therapeutics runs 2 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Calliditas Therapeutics was acquired in 2024.
- Calliditas Therapeutics AB: acquired in 2024
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Budesonide | Ends 2029 (exclusivity) | 5 |
A route B row is one company at one target.
Where its trials are
- Pregnancy and women's health: 2 trials led
- Urinary and reproductive: 2 trials led
- Digestive system: 1 trials led